Glaxo Wellcome Production is an API and finished-dose manufacturer based in France. It appears in 46 regulatory filings across 7 regulators, without an active US DMF or CEP on file. Its filings concentrate with ARCSA (EC), NAFDAC (NG) and INVIMA (CO). Its GMP standing is certified by ANSM (FR), ANVISA (Brazil) and MFDS (Korea), among 6 authorities. Its most recent recorded inspection, by US FDA, closed on 8 April 2022 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| MAYENNE, United Arab Emirates | Not on file |
| Evreux, United Arab Emirates | Not on file |
| MAYENNE, France | Not on file |
| NOTRE DAME DE BONDEVILLE, France | Not on file |
| France, France | 3002807436 |
| Evreux, France | Not on file |
1 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Fluticasone Propionate | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| ARCSA (EC) | 18 | None |
| NAFDAC (NG) | 7 | 2 |
| INVIMA (CO) | 6 | None |
| DIGEMAPS (DO) | 5 | None |
| UZPHARM (UZ) | 5 | None |
| MINSA (CR) | 4 | None |
| ANSM (FR) | None | 12 |
| ANVISA (Brazil) | None | 3 |
| MFDS (Korea) | None | 2 |
| EMA | None | 2 |
| FDA (GH) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2024 | $234.1M | Not reported | Not reported |
Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.
Choose your molecules and target markets. Glaxo Wellcome Production comes back tiered against every other supplier able to file there.
Start for free